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Electroencephalography (EEG) is a longstanding technique to measure electrical brain activity and thereby an
indirect measure of synaptic activity. Synaptic dysfunction accompanies Alzheimer’s disease (AD) and EEG can be
regarded as a potentially useful biomarker in this disease. Lately, emerging analysis techniques of time series have
become available for EEG, such as functional connectivity and network analysis, which have increased the possibilities
for use in AD clinical trials. In this review, we report the EEG changes in the course of AD, including slowing of the EEG
oscillations, decreased functional connectivity in the higher-frequency bands, and decline in optimal functional network
organization. We discuss the use of EEG in clinical trials and provide directions for future research.Review
Introduction
Alzheimer’s disease (AD) is a degenerative disease char-
acterized by pathological changes at the neuronal and
synaptic level that eventually result in dementia at the
subject level. The present therapeutic strategies have a
modest and only symptomatic effect. It therefore remains
essential to develop and test new interventional strategies.
Biomarkers can play a role as outcome measures in
clinical trials. Classically, outcome measures in clinical
trials in AD have focused on cognitive performance and
behavioral outcome [1]. However, these outcome mea-
sures provide limited information on the mode of action
of the pharmacological intervention, due to the lack of
knowledge on the exact relationship between the neuronal
level (where changes due to the intervention are assumed
to occur) and the cognitive-functional level. Biomarkers
can serve as a bridge between these two levels. Although
several authors mention the need for suitable biomarkers,
only few randomized clinical trials in AD have included
investigations other than the cognitive and behavioral
assessments [2].* Correspondence: i.vanstraaten@vumc.nl
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potentially can serve as biomarkers in AD clinical trials.
Magnetic resonance imaging, functional magnetic reson-
ance imaging (fMRI), cerebrospinal fluid analysis and
positron emission tomography each assess different brain
properties and are valuable for characterizing AD processes
[2]. However, these methods do not take into account
the high-frequency dynamics of brain activity, which is
a hallmark property of communication between neurons
and is expected to be impaired in AD [3].
Eyes-closed task-free (one of the so-called resting states)
electroencephalography (EEG) measures oscillatory elec-
trical brain activity and captures dynamical processes at
the macroscopic scale. This technique has potential use in
phase III trials because of its favorable investigational
properties: it is relatively inexpensive, widely available,
stable over time, and patient friendly. Additionally, recent
developments, such as the application of network theory,
increased the possibilities for EEG signal analysis of
contributing to the understanding the mode of action
of interventions in AD – in particular, in relation to
(synaptic) connectivity.
This paper aims to reassess the potential role of eyes-
closed task-free EEG in future AD clinical trials. We will
report and discuss the results of EEG analyses in AD
and in past clinical AD trials. We shall also review recentntral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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their use in future trials.Introduction to electroencephalography in Alzheimer’s
disease studies
EEG measures the fluctuating electrical field surround-
ing neurons. The EEG signal results from the sum of all
transmembrane currents picked up by the EEG elec-
trodes, where the most important contribution comes
from synaptic activity. Other currents include fast action
potentials, calcium spikes, intrinsic voltage-dependent
currents, ligand-gate ion fluxes, gap junctions, neuron–
glia interactions, and ephaptic effects [4]. Typically, the
number of EEG electrodes that are placed on the scalp
varies between 20 and 40, limiting the spatial resolution.
On the other hand, EEG picks up the fluctuations in
field potential with a very high temporal resolution (in
the order of milliseconds).
AD is pathologically characterized by widespread neur-
onal cell loss and depositions of amyloid and tau aggre-
gates, but previous studies have also suggested a link
between AD and synaptic dysfunction [3]. The synaptic
changes probably interfere with normal neuronal elec-
trical activity, even at rest when no specific cognitive
task is being performed, and eyes-closed task-free EEG
picks up this resting-state activity.
Recent technical advances have increased the possibil-
ities for EEG analysis. Digital EEG files usually have a
relatively small size, which allows fast electronic exchange
between recording centers; for example, for central ana-
lysis in multicenter trials. In addition, most parameter
settings are adjustable to the analytical needs at any time
after the recording. Furthermore, with increasing com-
putational power, classic frequency analysis as well as
advanced and complex studies of the EEG time series that
add information on the organization of brain function can
be performed.Electroencephalography frequency analysis
Computerized frequency analysis allows the objective
quantification of the different frequency components of
the complex digital EEG signal and is at the basis of many
different types of advanced EEG analysis. This analysis has
been widely applied in the context of AD.
EEG oscillations are often divided into several frequency
bands (bins of adjacent frequencies) – such as delta band
0.5 to 4 Hz, theta band 4 to 8 Hz, alpha band 8 to 13 Hz
(sometimes divided into alpha 1 band 8 to 10 Hz and
alpha 2 band 10 to 13 Hz), beta band 13 to 30 Hz, and
gamma band 30 to 70 Hz – and analyzed according to
these bands. Care should be taken when interpreting the
results of the gamma band, and to a lesser extent also the
beta band, since EEG activity above 20 Hz, and especiallyactivity above 30 Hz, is merely activity of the skull muscles
rather than of the cerebral cortex [5].
The absolute and relative quantities of each frequency
band within the total EEG signal are indicative of normal
or pathological conditions and can be used to detect
group differences. The dominant frequency, which is
seen as a peak in the frequency spectrum, typically lies
in the alpha frequency range in healthy awake adults.
The analysis of these frequencies is one of the most
widely available digital analysis techniques considering
that EEG recording and reviewing systems are increas-
ingly equipped with built-in tools for this purpose. In
addition, frequency analysis is computationally fast and,
since it is one of the most used analytical methods for
EEG, results can be weighed against previous research.
On the other hand, while the quantity of activity at a
certain frequency measured at an EEG electrode is related
to the amount of local synchronization of the underlying
neuronal population, there is limited information on the
phase relationship and synchronization between distant
brain regions.
The most consistent EEG finding in AD is diffuse slow-
ing of oscillations, displayed as an increased proportion of
theta and delta activity and reduced peak frequency [6,7].
Longitudinal studies found progressive slowing during the
course of the disease and also slowing in mild cognitive
impairment at the group level to varying degrees [8,9].
Figure 1 shows an example of the difference in the distri-
bution of relative power between a control subject and an
AD patient. Cross-sectional studies reported EEG abnor-
malities depending on patient groups: abnormalities can
be absent in late-onset AD and tend to be more prevalent
in AD beginning at younger age [10,11]. Apolipoprotein
E4 status has no unambiguous effect on EEG [12,13] and
the EEG findings correlate with decreased psychometric
performance in AD [14-16]. The mechanisms that cause
the progressive EEG slowing in AD are not completely
understood, but progressive loss of neuronal connectivity
through synaptic dysfunction might play a role [17]. This
view is supported by the findings that EEG slowing can be
modeled as decreasing connectivity between computer-
based neuronal assemblies [18] and that amyloid-beta tox-
icity primarily affects dendrites in AD [19]. On the other
hand, other mechanisms that may influence connectivity
between neurons, such as demyelination, might also be
considered and may be the subject of future modeling
studies.
Electroencephalography in clinical trials
The slowing of EEG oscillations has been used as a
marker for intervention effects in clinical trials, but the
results have varied. Administration during several weeks
to months of the approved AD treatments was not
found to have a consistent effect on EEG. However, the
Figure 1 Distribution of relative power across the brain. Color-coded relative electroencephalography power maps for each frequency band
of (A) a control subject (65 years old) and (B) an Alzheimer’s disease (AD) patient (66 years old, mild AD). Red, orange, and yellow, high relative
power; blue and green, low relative power. The patient has a higher proportion of slow (delta and theta) activity, whereas the control has a
higher proportion of faster (alpha) activity.
van Straaten et al. Alzheimer's Research & Therapy 2014, 6:86 Page 3 of 10
http://alzres.com/content/6/9/86trials were not double-blind controlled and therefore
definite conclusions with respect to the properties of
EEG as a marker in clinical trials cannot be drawn from
these studies [20-28]. Two more recent studies from one
double-blind controlled intervention trial in mild AD
reported considerable information on trial design and
procedures, which facilitates appreciation of the results
[29,30]. These studies used frequency analysis (peak
frequency and relative power), in addition to the more
advanced functional connectivity and network analyses,
as the EEG outcome parameter. The studies report that
a 24-week intervention with medical food that was
designed to enhance synaptic formation and function
stabilized the peak frequency, whereas the control group
declined on this measure. This indicates that, in untreated
mild AD patients, a decline in peak frequency from base-
line can be observed at a group level in the course of
6 months, and peak frequency is sensitive enough to pick
up an intervention effect in this patient group.
The methodological differences and suboptimal trial
designs of most intervention studies render the results
difficult to interpret. Most studies are relatively old
(before 2001) and do not meet the current standards on
clinical trial design and reporting, such as a description
of the randomization, the use of blinding, the description
and statistical handling of dropouts, and the trial registra-
tion number. Furthermore, the number of participants is
generally modest, with patient groups smaller than 20.
These trial properties should prompt caution when inter-
preting and comparing the results.
Overall, the studies show that it is feasible to implement
EEG in clinical trials and there are indications that peak
frequency is sensitive to an intervention effect. Due to the
insufficient quality of most clinical trial designs, most ofthe currently available EEG results are difficult to appreci-
ate, but future studies that have implemented the present
standards for clinical trials could resolve this issue.
Functional connectivity
Lately, the field of EEG analysis has advanced consider-
ably and analysis methods beyond the classic frequency
analysis have become available for AD research. One of
these relatively new analyses is functional connectivity
(see [31] for an overview of connectivity measures). The
basis of functional connectivity lies in the notion that
complex brain function, including cognition, requires
large-scale integration of locally generated neural activity
and that the synchronization of the activity between
distributed brain areas is thought to reflect this integration
[32]. Long-distance synchronization, as an approximation
of functional connectedness, is quantified by the assess-
ment of the statistical interdependency between time
series (for which EEG next to fMRI and magnetoencepha-
lography (MEG) is used) [31]. The resulting functional
connectivity values indicate the strength of the functional
coupling, based on the similarity of the signals (Figure 2).
In addition to the most commonly used undirectional
measures, effective connectivity measures exist that not
only study the connectivity strength but also its direction,
although care should be taken when interpreting the re-
sults with respect to the underlying biological dynamic
processes.
The number of functional connectivity studies, including
those that use EEG, in AD is rapidly increasing and AD-
related connectivity changes are starting to become clear.
Especially in the higher-frequency bands, AD patients have
lower functional connectivity than controls [34,35]. More-
over, the connectivity changes are not equally distributed
Figure 2 Electroencephalography-based functional connectivity. Functional connectivity (FC) is based on the phase lag index, filtered in the
alpha 2 band (Fp1, Fp2, A1, and A2 excluded). (A) Distribution map for average FC of a healthy subject. (B) Distribution map of average FC for an
Alzheimer’s disease patient. (C), (D) Adjacency matrices of the control subject from (A) and the patient from (B), respectively, showing the strength of
the pair-wise FC values. X and Y axes, electrode number; cells, color-coded FC value of the corresponding electrode pair. Red, high FC value; blue, low
FC value. FC is generally lower in the patient. Pictures generated with BrainWave software version 0.9.117 [33].
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increases as well as decreases have been described [36].
Positive relationships between decreased functional con-
nectivity and impaired cognitive performance seem to be
present [35,37]. Knyazeva and colleagues showed that the
decrease of functional connectivity is related to the rate of
cognitive decline in a 1-year follow-up study, but only in
rapidly progressive patients and only in some specific brain
areas that are known to be involved early in the AD
process (especially the left-sided, lateral, and medial tem-
poral regions) [38]. In addition, varying results were
reported in mild cognitive impairment.
The application and interpretation of this new method
requires knowledge about some methodological issues.
One of these issues is the fact that the choice of the
functional connectivity measure influences the results[39-41]. Ansari-Asl and colleagues showed in a model
of coupled neural masses that the Pearson’s correlation
coefficient was most sensitive to modeled connectivity,
but in a model of a Rössler coupled system, for example,
the synchronization likelihood was most sensitive [39].
David and colleagues reported that for broadband ana-
lysis the methods based on generalized synchronization
are more sensitive than methods which use mutual
information, but for narrow-band signals the opposite
is true [40].
For intracranial EEG in rats, several connectivity mea-
sures – except for a mutual information measure – per-
formed qualitatively comparably [41]. Additionally, each
functional imaging method (EEG, MEG, fMRI) has
modality-specific difficulties. For EEG, a major challenge
is the ‘common-source problem’: when activity from one
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trodes, the electrodes have perfect zero-lag phase coupling.
This common-source effect, or volume conduction, could
lead to artificially high functional connectivity values for
neighboring brain areas that do not reflect true functional
coupling of separate neuronal systems. Zero-lag phase
relations can be excluded using novel synchronization
measures, but this, in turn, has the disadvantage of also
excluding true zero-lag interactions [42,43]. EEG-derived
functional connectivity is therefore either biased towards
short-distance connections (when measures are used that
include zero-lag phase relations) or towards longer-distance
connections (when zero-lag relations are excluded). Other
factors that influence connectivity results are the choice of
the reference electrode and the choice of the length of the
selected time series, both of which are not standardized
in the field of functional connectivity research. Methodo-
logical differences between studies account for at least part
of the difference in results and future studies are needed
to further assess the relationship between methods.
In conclusion, the EEG-based functional connectivity
in high-frequency bands is generally lower in AD than in
controls. The significance of this finding lies in the
support that it gives to the involvement of large-scale
brain communication in this type of dementia and thereby
to the involvement of synaptic activity. This is in line
with the quantitative EEG analysis results regarding the
concept of synaptic loss: the AD process is accompanied
by a loss of synapses that induces a loss of long-distance
functional connectivity which is picked up by EEG con-
nectivity measures. However, other processes might also
contribute to the reduction of EEG functional connectivity
in AD; for example, by interfering with the timing of
synaptic firing or other cortical processes that influence
EEG signals. One of these processes might be demyelin-
ation, which has been demonstrated to be present in AD
in the white matter underlying the cortex [44]. Future
studies can further characterize the changes in functional
connectivity in AD to increase the understanding of the
effects of AD-related pathophysiological mechanisms on
brain dynamics and thereby to decrease the gap between
the neuronal level and the behavioral level of impaired
cognition.
Network analysis
Lately, graph theoretical analysis of complex networks
has been implemented in brain research, including AD
studies (for a review on brain networks, see [45]). Brain
network analysis uses the analysis of functional connect-
ivity by integrating the pair-wise functional correlation
values into one network that can be characterized. In
the case of EEG, network nodes are usually the brain
regions underlying the electrodes and the functional
connectivity value of each node pair (usually representedin a connectivity matrix) is used as a functional connection
between nodes.
As an example, Figure 3 shows a graphical representa-
tion of a network with 78 nodes, based on an MEG
study from an AD patient. Network analysis quantifies
higher-order patterns of the set of connections, such as
the distribution of the connections across the nodes, and
thereby uncovers information on the organizational prop-
erties of the functional network that extends beyond
the functional connectivity analysis alone. This network
perspective has revealed some aspects of the large-scale
organization of cerebral activity: when regarded as a
complex network of interconnected units (based on the
functional connectivity values), functional brain networks
fit the mathematical models for small-world (optimally
combining short-distance connectivity and long-distance
integration) and hierarchical modular organization (with
inter-nested communities of highly interconnected nodes)
better than the model of random networks [46-48].
The strengths of the network approach in AD studies
include the implementation of a theoretical framework
and powerful mathematical models to study the determi-
nants of network disruption in AD. The mechanisms
that change the macroscopic functional organization in
AD might contribute to our understanding of the clinical
signs as well as the pathophysiological processes in this
disease. In addition, the theoretical framework of network
analysis is invariant of the modality used and can be
applied to any study that consists of measurement points
with a relationship between these points. This facilitates
the integration of results of brain mapping techniques,
including time series (fMRI, EEG, MEG), structural stud-
ies (magnetic resonance imaging) and metabolic and
perfusion studies (positron emission tomography, single-
photon emission computerized tomography).
Indeed, the EEG-based functional brain networks of AD
patients have been found to differ from those of healthy
individuals. In one study, a change from the optimal
small-world network configuration into a disorganized,
more random network type was found in the higher-
frequency bands, although volume conduction effects
were included in this study [49]. In the lower-frequency
bands this pattern is opposite, and both patterns have
been found in the intermediate alpha 1 band [49,50]. AD
seems to influence functional networks in a nonhomoge-
neous manner: the quantity of regional amyloid deposition
has a linear relationship to the number of functional
connections of that region [51]. The brain areas with a
high level of functional connectivity (so-called hubs) and
also a high amyloid load include the posterior cingulate
and precuneus, the lateral temporal and parietal cortices,
and parts of the prefrontal cortex. A computer model
study showed that damaging the functional brain network
as a function of the number of connections is more
Figure 3 Representation of a magnetoencephalography-based functional brain graph with 78 brain regions (network nodes indicated
by numbers). Connections (lines between nodes) are the thresholded functional connectivity values (phase lag index) between node pairs.
(A) Transversal view, frontal up. (B) Sagittal view, frontal left. Colors indicate clusters of brain regions that have a higher connectivity within the
cluster than outside the cluster (modules). A predominance of midline transversal connections can be seen. Pictures generated with BrainWave
software version 0.9.117 [33].
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[18]. Additionally, another computer model suggested
that the level of electrical activity, measured as spike
density and total power, in a brain area increases with
the number of connections in that area [52]. Taken to-
gether, the cross-sectional network analyses support the
hypothesis that AD is a hub disease, with largest damage
to the most central, well connected, and electrically most
active brain regions resulting in disruption of the efficient
small-world hierarchical modular network organization.
One double-blind controlled intervention study used
graph theoretical measures as secondary outcome mea-
sures [29]. In this study, functional brain networks of a
group of mild AD patients receiving medical food that
aimed to enhance synaptic formation and function were
stable during 6 months, whereas the networks of the con-
trol group seemed to change in the direction of more ran-
domness (with decreasing values for the clustering
coefficient as a measure of local connectivity and for the
path length as a measure of global integration).
Although a general pattern of AD-related network
changes is emerging from the literature, methodological
differences between studies influence the results, redu-
cing the comparability across studies [53,54]. Functional
brain networks are derived according to different strat-
egies. One of the most straightforward networks is the
unweighted network: connections are defined by setting a
threshold, and only the connectivity values that exceed
the threshold are included in the network. As a result, the
network matrix is binary (the connections are yes/no
present) and all connections have equal strength. Thehandling and visualization of these unweighted networks
is relatively easy. On the other hand, determining the
threshold value is arbitrary and the network values are
heavily influenced by the functional connectivity values. A
high threshold results in networks with fewer connections
than a lower threshold and results in network values
that indicate a decrease in local connectivity and global
integration. In addition, applying an equal threshold to
networks of different groups of subjects could result in
unconnected nodes and differences in network size. Size
differences hamper comparison between networks.
An alternative approach is the construction of
weighted networks, in which the exact values of the
connectivity matrix are preserved without the need for
thresholding. Nevertheless, functional connectivity also
influences weighted network measures to a great ex-
tent. A partial solution to this problem is normalizing
the weighted networks. This can be done by presenting
the network measures as proportions of measures of a
set of random networks with equal connectivity
strength, derived from shuffling the functional connect-
ivity matrix. However, it has become clear that the
resulting random networks are not really random and
still contain a great deal of structure. In addition, the
methodological differences in the computation of func-
tional connectivity also influence network results, since
the functional connectivity values are used for the com-
putation of functional networks. The use of methods
that do not require arbitrary parameter settings but
uniquely follow from the connectivity matrix can
resolve some of these problems.
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[55]. Figure 4 shows the workflow for constructing a
minimum spanning tree. Here, four EEG epochs of
8.2 seconds for a healthy subject were used as input and
the functional connectivity matrix for this subject was
computed. Instead of taking the full matrix, only the
connections with the highest values are considered for
further network analysis in such a way that all nodes are
connected and no loops are formed. While this method is
unbiased, the minimum spanning tree consists of a rela-
tively low number of connections and may under-represent
less strong, but nonetheless important, connections. Also,
the loopless structure of the network is not typical for the
underlying microscopic brain connectivity, which consists
of numerous feedback and feedforward loops, making this
network somewhat more indirect. One fMRI study showed
that the organization of such networks is disturbed in AD
[56]. Whether minimum spanning tree changes in EEG in
AD can be found remains to be studied, but changes were
found over the course of 2 years in healthy children and
after sleep deprivation in children with focal epilepsy
[57,58].
Although a longitudinal MEG study found network
changes to be correlated with the decline in cognitive
performance in Parkinson’s disease, the longitudinal
behavior of network changes in AD has not so far beenFigure 4 Example of an electroencephalography-based minimum spa
electroencephalography epochs used for the analysis. Every line is the time se
adjacency matrix with the functional connectivity values of each electrode pa
showing only the highest 20 connectivity values of the network without loop
modules. Pictures generated with BrainWave software version 0.9.117 [33] (A,studied. It can be conceived that the changes do not
relate linearly to disease progression, as is the case for
other modalities such as hippocampal atrophy and mem-
ory scores, and that the yield of EEG network measures
in clinical trials for AD depends on the AD severity. To
what extent network measures suffer from floor or ceiling
effects, which could make them less sensitive in earlier or
later disease stages respectively, is currently insufficiently
known. Longitudinal studies, as well as measuring an
intervention effect in different AD stages, will help to
establish the value of this type of marker.
Conclusions
This review presents an overview of eyes-closed task-
free EEG analysis methods that are potentially useful in
AD clinical trials and discusses past intervention studies
implementing EEG in AD. Studies using conventional
methods show a converging pattern of change in AD.
This pattern of slowing of EEG oscillatory activity may
serve as a benchmark in intervention studies. In addition,
newer analysis methods, such as functional connectivity
and network analysis, have been applied to EEG in AD
and, when implemented in clinical trials, can contribute to
the understanding the mode of action of the interventions.
For example, an intervention-related preservation of local
connectivity that is distributed across the brain regionsnning tree of a healthy subject. (A) Part of one of the four
ries of one electrode. (B) Phase lag index-based functional connectivity
ir. (C) Minimum spanning tree matrix derived from the matrix in (B)
s. (D) Graphic representation of (C), colors indicate different network
B, C) or Gephi version 0.8.2 (D) [59].
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intervention is especially effective in hub regions and
thereby in the brain regions with the highest electrical
activity and the highest metabolic demand. In addition,
different intervention effects on long-distance and short-
distance connectivity indicate what systems might be
involved. However, it is presently too early to apply
functional connectivity and network analyses for these
hypotheses and more knowledge on the behavior of the
network and connectivity measures is needed to fully
understand their meaning.
The value of EEG in clinical trials will improve when
it is implemented in high-quality randomized clinical
trials. So far, most controlled trials using EEG are very
small and do not report enough details on the trial design
and trial execution to assess the risk of bias. Furthermore,
most studies are relatively old and not designed according
to the current standards. However, with advances in
designing and reporting of randomized controlled trials,
future studies can address these problems. We recommend
that the quality standards which apply to the performance
of clinical trials should also be implemented in the EEG
part of future studies.
In addition, knowledge of the influence of the type of
EEG analysis can improve comparison of results between
studies. No universal method exists at each analysis level
(quantitative analysis, connectivity analysis, and network
analysis) and each method influences the outcome. Con-
sequently, studies that use different analysis techniques
are difficult to compare. When test characteristics are
taken into account, however, differences in results might
explain differences between studies and might even give
additional information on the mode of action. The strat-
egy of using multiple measures and searching for a con-
sistent direction of connectivity changes in AD across the
methods has the advantage of increasing knowledge on
the behavior, such as sensitivity, specificity, availability,
and applicability, of the different measures relative to each
other. An alternative approach would be to further subdiv-
ide functional connectivity into categories based on the
characteristics of the synchronization measures, such as a
subdivision into short-distance and long-distance biased
connectivity. In this way, it may be possible to interpret
the results of different connectivity measures in addition
to, rather than instead of, each other. In parallel, there is a
need for the development of EEG analysis techniques that
do not depend upon the often arbitrary choice of one or
more parameters. The availability of an EEG analysis
method that has good discriminative properties and
which renders results without a single choice in param-
eter settings could be valuable for reaching consensus.
At this moment, clinical measures are the only accepted
endpoints for pivotal phase III intervention studies in AD
[60]. It is also known that clinical signs do not linearlyrelate to cell loss or the characteristic AD pathology of
tangles and plaques. Cellular changes precede cognitive
disturbance, but the exact temporal relationship remains
unclear. One study has reported a relationship between
cellular loss in the entorhinal cortex and loss of cog-
nitive performance prior to, more than during, AD [61].
Additionally, the pathological AD features vary over the
cortical regions, and the quantification of AD pathology is
therefore also variable and dependent on the regions of
interest and sampling. At the other end, performance on
cognitive testing is also subject to other factors than the
AD process. Typically, performance varies in time to a
certain extent due to fluctuations in concentration, learn-
ing effects, and other intrinsic and extrinsic factors. There
are therefore several arguments as to why looking only
at clinical performance is not sufficient to understand
an intervention effect in an AD trial. Coordinated brain
activity, such as measured by EEG, and its large-scale
organization are becoming increasingly identified as mean-
ingful brain characteristics and possible candidates for the
assessment of interventions in AD [62].
In conclusion, EEG in clinical trials in AD is a feasible
and potentially useful addition to cognitive endpoint
measures in AD trials. Recent developments in EEG
signal analysis, such as network analysis, present promis-
ing methods to provide frameworks for the testing of
hypotheses on the mode of action of interventions.
When the quality of the clinical trial design and analysis
meets the current standards, the role of EEG in clinical
trials for AD can be fully appreciated.
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